In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra®) has been developed and has replaced Vivaglobin® (SCIG 16%).An observational prospective multi-centric open-label study, with retrospective comparison was conducted in 15 Italian centers, in order to investigate whether and to what extent switching to Hizentra® would affect frequency of infusions, number of infusion sites, patients’ satisfaction, and tolerability in patients previously treated with Vivaglobin® or intravenous immunoglobulins (IVIG).Any variations of dosage, frequency and duration of the infusions, and of number of infusion sites induced by Hizentra® with respect to the former treatment were recorded. Practical advantages and disadvantages of Hizentra®, with respect to the medicinal product formerly used, and the variations in patients’ therapy-related satisfaction were monitored by means of the TSQM (Treatment Satisfaction Questionnaire for Medication); number, frequency, and duration of infectious events and adverse effects were recorded.Eighty-two patients switched to Hizentra®: 19 (23.2%) from IVIG and 63 (76.8%) from Vivaglobin®. The mean interval between infusions was not affected by the shift (7.0 ± 2.0 days with previous treatment versus 7.1 ± 1.2 during Hizentra®). A decrease in the number of infusion sites with Hizentra® was recorded in 12 out of 56 patients for whom these data were available. At 6 months, 89.7% of patients were satisfied with Hizentra®; no difference in terms of effectiveness, side effects, convenience, and global satisfaction was observed. No difference in the incidence of adverse events was reported.
The administration of 20 % SCIg was beneficial and safe in maintaining a quiescent disease and in inducing a complete remission in moderately active disease in patients with DM or PM. The treatment with 20 % SCIg led to the possibility to discontinue and to reduce the use of glucocorticoids and/or the immunosuppressants. Patients reported their satisfaction in terms of contact with health professionals, quality of treatment-related information and administration convenience, with an improved quality of life.
Common variable immunodeficiency is the most common symptomatic primary immunodeficiency in adulthood. Pregnant women with common variable immunodeficiency have different needs from other patients with the same disease. Because of immature state of the fetal and neonatal immune system, transplacental transfer of immunoglobulin G (IgG) has a relevant role in protecting the infant. We here report on a high-risk pregnant woman with common variable immunodeficiency with adverse reactions to intravenous immunoglobulin that was successfully rescued with a new Ig human intravenous, 10% liquid preparation. The treatment was tailored to the health status and characteristics of the patient. The new product was safe and well tolerated. The mother did not report any infections during pregnancy and the baby had a healthy course with ‘protective’ serum IgG levels. Our case is a further demonstration that intravenous immunoglobulin tolerability in patients with immunodeficiency could be linked to a product's characteristics.
Objectives To describe disease outcome and the influence of treatment modalities in a cohort of patients with polymyositis (PM) and dermatomyositis (DM) prospectively followed by our Internal Medicine Department, between 1985 and 2013. Methods We reviewed the medical notes of 91consecutive patients with PM and DM diagnosed according to the Bohan and Peter criteria. Since the diagnosis each patient have been followed by a standardised protocol. In March-May 2013 all of patients were enrolled in this study with the objective to evaluate a) the disease outcome b) disease activity, c) damage due to disease and treatment d) and the influence of treatment in outcome in the course of the disease. Results The series comprised 91 subjects with either PM (43) or DM (48) (Table 1). Myogenic abnormalities were detected by EMG in all of the cases, whereas muscle biopsy confirmed the diagnosis in 78% of the cases. All patients were treated with glucocorticoids. 72 patients (78%) received one (n=18) or more (n=31) agents, such as immunosuppressants, IVIg (in 39 patients), SCIg (n=18). Twenty-two patients (24%) (12F =55%; mean age 66 years) died after a mean follow-up of 91±84 months. According to the age-adjusted Cox regression model, male sex and a high MITAX value at the onset significantly correlate with mortality [HR =2.4, 95% CI =1.0 to 5.6 and HR =1.5 (95% CI =1.1 to 2.1), respectively]. Kaplan-Meyer estimates higher mortality for patients treated with corticosteroids or with corticosteroids and immunosuppressants as compared to patients treated with IVIG and/or SCIg (LR test p-value =0.3). Five-, 10- and 15-year survivals were higher in patients treated with immunoglobulin as compared with those treated with glucocorticoids or glucocorticoids plus immunosuppressants (p<0.08,0.1 and 0.06,respectively). Conclusions PM and DM represent complex systemic disorders with a high rate of mortality. Patients initially treated with glucocorticoids and/or immunosuppressants had poorer outcome as compared with those treated with immunoglobulin (IV or SC). Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.3245
Background We here report the incidence, the clinical features and treatment response of interstitial lung disease (ILD) associated to idiopathic inflammatory myopathies (IIM), Sjogren’s Syndrome (SS) and systemic lupus erythematosus (SLE). Methods We reviewed the clinical notes of 224 consecutive patients followed by our department from 1990 to 2011. IIM was present in 77 patients, SS in 100 subjects and SLE was documented in 87 cases. Demographic, clinical and serological data were collected through a standardised protocol. ILD was defined by specific spirometric and tomographic patterns. Results ILD was documented in 20 (26%) patients with IIM, in 15 (15%) with SS and in 13 (15%) with SLE. All patients were treated with steroid, alone or associated with an immunosuppressant. All of them had a restrictive pattern at the pulmonary function testing with a reduced diffusing capacity for carbon monoxide. In patients with SS- and LES- associated ILD the response to the treatment was satisfactory, whereas in patients with myositis, ILD-related deaths occurred in 25% of the cases. This percentage was higher when compared to the percentage of the disease-related death (17%). Conclusions Despite major progress in the treatment, ILD in the course of CTDs remain a severe complication, significantly affecting subjects’ survival and quality of life. The relatively high frequency of asymptomatic subjects, with subclinical ILD documented by the presence of a restrictive spyrometric pattern and typical radiological features, suggests the importance of early diagnosis. Disclosure of Interest None Declared
Background We have previously demonstrated the beneficial effect and the safety of subcutaneous immunoglobulin (SCIg) administration in active and refractory inflammatory myopathies. Hizentra (IgPro20; CSL Behring) is the first, 20% liquid preparation of human IgG specifically formulated for subcutaneous infusions. We here report on the switch to weekly subcutaneous infusions of Hizentra(®) in inflammatory myopathies. Objectives We demontrate efficacy of the new formulation of subcutaneous immunoglobulins with quality of life improvement. Methods Six severe idiopathic myositis (four with DM, two with PM), diagnosed according to the Bohan and Peter’s criteria, were switched to weekly subcutaneous infusions of Hizentra(®) at doses equivalent to their previous subcutaneous treatment. A standardized protocol including the Medical Research Council (MRC) scale, the modified Rankin score, CK serum levels and daily prednisone dose, was used to evaluate patients and to assess disease activity, treatment response and quality of life. Results All patients showed a favourable clinical response with normal CK serum levels and improvement in MRC and Rankin modified scores. No relapse of the disease occurred: patients reported a good tolerance to Hizentra (®). Local reactions were mild and self-limiting (only one patient showed swelling). No serious Hizentra(®)-related adverse events were reported whereas they pointed an improved quality of life. Patients’ satisfaction was related to the shorter infusion times due to smaller infusion volumes, the easiness to handle the product and the possibility to store it a temperature up to 25°C. Conclusions Hizentra is an advance in the field of immunoglobulin therapy, which might offer benefits for home therapy, even in patients with autoimmune diseases. Disclosure of Interest None Declared
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.